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Abstract
Biologic therapies have shown high efficacy in psoriasis, but individual response varies and is 
poorly understood. To inform biomarker discovery in the Psoriasis Stratification to Optimise 
Relevant Therapy (PSORT) study, we evaluated a comprehensive array of omics platforms across 
three time-points and multiple tissues in a pilot investigation of ten severe psoriasis patient, treated 
with the tumor necrosis factor (TNF) inhibitor, etanercept. We used RNA-sequencing to analyse 
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mRNA and small-RNA transcriptome in blood, lesional and non-lesional skin and the Somascan 
platform to investigate the serum proteome. Using an integrative systems biology approach, we 
identified signals of treatment response in genes and pathways associated with TNF signalling, 
psoriasis pathology and the MHC region. Notably, we found association between clinical response 
and TNF-regulated genes in blood and skin. Using a combination of differential expression testing, 
upstream regulator analysis, clustering techniques, and predictive modelling, we demonstrate that 
baseline samples are indicative of patient response to biologic therapies, including signals in 
blood, which have traditionally been considered unreliable for inference in dermatology. In 
conclusion, our pilot study provides both an analytical framework and empirical basis to estimate 
power for larger studies, specifically the ongoing PSORT study, which we demonstrate as powered 
for biomarker discovery and patient stratification.
Introduction
The introduction of biologic therapies into clinical practice has led to major improvements 
for patients with severe psoriasis. However, optimal, cost-effective provision of these 
therapies in a resource-limited healthcare system will necessitate a stratified approach 
(Griffiths, 2017, Lebwohl, 2016).
Translational research has been revolutionized by the availability of technologies to measure 
features of the genome, transcriptome, and proteome (so called “omics”), primarily 
facilitated by high-throughput sequencing (HTS, formerly next generation sequencing). It is 
likely that data generated by these new technologies will inaugurate an era of stratified care 
founded on comprehensive cellular profiles, rather than individual biomarker molecules 
(Johnston et al., 2017). Such laboratory methods have already been employed in 
dermatological research to identify biomarkers of treatment response in inflammatory skin 
disease (Correa da Rosa et al., 2017, Ungar et al., 2017), but validation of those markers 
remains elusive and unlike our colleagues in oncology, clinical dermatologists have yet to 
see the integration of omics into daily practice.
Methodological problems have in part hampered the translation of pharmacogenomic results 
into clinical success in dermatology (Jorgensen and Williamson, 2008). Well-designed and 
adequately powered prospective studies are required to identify clinically robust biomarkers. 
Psoriasis Stratification to Optimise Relevant Therapy (PSORT) is an academic-industrial UK 
stratified medicine consortium funded by the Medical Research Council and devoted to 
developing a stratifier of response prediction to biologics, scalable for clinical use for those 
with moderate to severe disease (Griffiths et al., 2015).
In order to inform the analytical strategy of PSORT, we conducted a pilot study to evaluate 
response to a biologic in psoriasis patients using lesional (PP) and non-lesional (PN) skin 
and blood, and a range of omic platforms and different analysis pipelines. In addition to 
comparing the performance of each platform and tissue, we used our preliminary data to 
obtain an empirical estimate of the required sample size to adequately power the full PSORT 
study. Here we report the results of a comprehensive multi-omic pilot study (Figure 1), 
including RNA sequencing (RNA-Seq) of mRNA PP and PN skin, RNA-Seq from mRNA 
and from miRNA from blood as well as Somascan proteomic data from blood.
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Our tightly phenotyped, rigorously controlled cohort of patients with severe chronic plaque 
psoriasis commenced biologic therapy with the tumor necrosis factor inhibitor (TNFi), 
etanercept. We evaluated the relative merits of each platform and demonstrate a workflow 
for scaled use on large datasets. We provide not only open data but open access to our 
complete analysis scripts and a fully executable R Markdown document for colleagues to 
evaluate and exactly reproduce the workflow themselves (Foulkes et al., 2017). Multi-omic 
analysis is a highly resource intensive process, particularly with the breadth of approaches 
described here, which are beyond the resources of most projects. We use this pilot study to 
comment on the relative merits of multi-omic approaches and highlight platforms that show 
particular promise in predicting response to therapy.
Results
Patient Characteristics and Analysis of Clinical Response
Ten patients commencing etanercept therapy were recruited from a prospective clinical 
observational study entitled pharmacogenomic signatures of treatment response in psoriasis. 
Figure 1 provides an overview of the study and patient characteristics for included 
participants are shown in Table 1. Participants were assessed at baseline, week one and week 
12 of therapy and response to therapy was determined using the Psoriasis Area and Severity 
Index (PASI), with a response defined as a reduction of PASI by at least 75% from baseline 
(PASI75) and non-response defined as failure to achieve a reduction of at least 50% from 
baseline (PASI50). Supplementary Figure 2 demonstrates a scatterplot of PASI at baseline 
vs. PASI at week 12.
Multi-omic analysis
Using samples from each participant at each time-point (one biopsy sample per library), we 
performed RNA-Seq on mRNA from PP skin (60m paired reads/sample), PN skin (60m 
paired reads/sample), and blood (30m paired reads/sample). We additionally performed 
RNA-Seq on miRNA from blood (10m single reads/sample) and Somalogic proteomic 
assessment on serum samples. As exploratory data analysis is a key first step in multi-omics, 
we first constructed a sample similarity matrix to compare mRNA transcriptome across 
tissues, by calculating the pairwise Euclidean distance between all mRNA samples 
(Supplementary Figure 2). Samples were clearly separated by tissue, although less 
distinction was seen between PP and PN skin samples, in part reflecting strong intra-subject 
effects and treatment effects between baseline and 12 weeks. Next we examined 
transcriptome structure on a tissue-by-tissue basis using two different projection methods. 
Principal component analysis (PCA) demonstrated clear separation between skin and blood 
along the first principal component, as expected (Supplementary Figure 3a). The second 
principal component separated PP from PN samples, albeit with one data point 
corresponding to a participant’s week 12 observation. This patient showed good response to 
therapy, suggesting putative detection of remission at mRNA transcriptome level. Similar, 
although less distinct tissue separation was seen by another projection method, t-distributed 
stochastic neighbour embedding (t-SNE) (Supplementary Figure 3b). Tissue-wise projection 
plots across all platforms were dominated by intra-subject signatures (Supplementary 
Figures 4 and 5). These unsupervised methods do not appear to separate patients by 
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treatment response, indicating that supervised techniques may be required to detect a 
response signal in these data.
Response differential expression analysis by platform
Differential expression analyses (DEA) to investigate the effects of etanercept treatment over 
time were performed for each platform (mRNA-Seq, miRNA-Seq and Somascan proteomic 
assessment), and tissue type (PP skin, PN skin and blood) using a common limma analytical 
framework. Access to our complete analysis script and fully executable R Markdown 
document allows reproduction of this workflow with evaluation of these results (see 
Materials and Methods and Supplementary File). We imposed a 10% false discovery rate 
(FDR) threshold. We selected this cut-off because power calculations suggest the modest 
sample size of the study will impede our sensitivity to detect differential expression. A 10% 
FDR threshold is therefore likely to underestimate the true number of differentially 
expressed genes or proteins in our dataset.
A summary of differential expression of mRNA, miRNA and protein across time and across 
tissue types may be found in Figure 2, whilst all differentially expressed molecules are 
summarised in supplementary table 1.
Heatmaps of the top 1% gene expression changes from PP skin, PN skin, and blood are 
shown in Supplementary Figure 6. The top 1% of genes cluster by response to treatment 
across PP, PN skin and blood. Similar results were seen with supervised and unsupervised 
cluster assignments.
Upstream regulator analysis
Acknowledging that our study is not powered for discovery, we used the Upstream 
Regulator Analysis function in Ingenuity Pathway Analysis (IPA) to evaluate upstream 
regulator signals at a systems-level that may be responsible for the observed gene expression 
changes. Upstream regulators are defined as any molecule that can affect the expression of 
another molecule, including transcription factors, cytokines, miRNAs and drugs. The 
activation state for each regulator was predicted based on global direction of changes in the 
DEA for previously published targets of this regulator. The predicted top 30 regulators 
across all tissues and time points are shown in a hierarchically clustered heatmap in Figure 
3. Results demonstrate a range of pro-inflammatory signalling and drug pathways, including 
a highly conserved, pan-tissue TNF signature, strongest at baseline in blood and at week-1 
in PP and PN skin, and substantially diminished at week-12 across all tissues. A similar 
pattern is also seen in Figure 3 hierarchically clustered with TNF in Interferon α−2 and γ 
signalling, in addition to NFΚβ signalling. This is an interesting proof of concept of the 
ability to detect a biologic drug response at a systems level, which we discuss further below.
Platform comparison
Baseline Omic Platform Concordance—We performed supervised and unsupervised 
PAM (Partitioning Around Medoids) clustering on baseline samples for each tissue across 
all platforms, relating the differentially expressed genes from each platform to response and 
informing where drivers of prediction to response have commonalities. Cross-platform 
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concordance was evaluated using the mutual information between cluster assignments, 
indicating a wide range of concordance values among supervised clusters (Figure 4a). 
Lesional mRNA and blood mRNA concordance was highest at 0.88 bits.
Machine Learning Models—We built a series of random forest models to predict 
continuous response using baseline data from each tissue-type and platform (Figure 4b). 
Predictive power was detected across platforms using this methodology, demonstrating 
additional signal to the differential expression analyses. The proteomics assay, in which we 
found no significant differentially expressed proteins at baseline using traditional marginal 
techniques (i.e., looking at each feature separately), proved the most predictive platform for 
response when modelled using random forests; however differences between data types were 
generally insignificant. The recursive feature elimination algorithm we used for these 
models (see Methods) may provide an alternative approach to biomarker discovery, offering 
insight into omic signatures of response. Our top-performing model achieved a root-mean-
square error (RMSE) of 0.123, which is just less than 75% of the standard deviation of our 
(winsorised) delta PASI distribution.
Power calculations for a prospective observational study
Using the method of Guo et al. (Guo et al., 2014) and parameters derived from this pilot 
study, we calculated the requisite sample size to achieve 90% power to detect differential 
expression associated with response. Using the pilot data presented here as a guide, we 
project that 17,000 genes are likely to pass a reasonable expression filter, and that some 1% 
of these genes will prove prognostic in a sufficiently large cohort. The top 1% of genes in 
our baseline measures had an average read count of ~100 prior to normalisation; a minimum 
log fold change of approximately 0.72 after modelling; and a global dispersion estimate of 
0.137, as estimated by the empirical Bayes procedure of McCarthy et al. (2012). Imposing a 
5% FDR threshold and a target log fold change of 1.5, we find that a study would require 41 
subjects to achieve 90% power to identify transcriptomic markers of biologic response for 
patients with chronic plaque psoriasis. Relaxing the number of differentially expressed genes 
to 5%, we can maintain 90% power with 34 subjects. We present power curves projected 
across an expected range of fold changes at 1% and 5% DE in supplementary figure 7.
Discussion
These results were presented at the 66th annual Montagna Symposium on the Biology of 
Skin. In this study we present a framework for multi-omic analysis of biologic response. Our 
results are transparent and fully reproducible via companion markdown documents. This 
makes our analysis framework suitable for larger studies of similar nature, such as the 
PSORT program. We emphasise that this proof of concept study is not powered for 
discovery; however, our results do suggest that signals of response to therapy in patients 
with severe psoriasis treated with the TNFi etanercept may be systemically detectable in 
lesional skin, non-lesional skin and blood at baseline, prior to commencement of therapy. 
Evidence of differential expression correlated with treatment response was observed across 
all tissue types and time points, but differed across omic platforms.
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The choice of the TNFi etanercept related to the timing of study design and the observed 
rates of etanercept response were within the range observed in studies of larger cohorts 
(Leonardi et al., 2003). Prior pharmacogenomic evaluations of patient cohorts have centred 
on the use of genetic or genomic techniques, predominantly using skin biopsies, although 
several studies have used skin and blood (Chow et al., 2016, Suárez-Fariñas et al., 2012), 
with consideration of detection of response early in treatment. Whilst no prospective 
biomarkers have yet been validated in adequately powered cohorts, there has been 
substantial progress, with the creation of predictors or classifiers of response (Correa da 
Rosa et al., 2017).
Our focus was RNA-Seq technology as the gold standard for gene expression profiling. 
RNA sequencing provides counts of all the genes expressed in a sample including 
microRNAs (miRNAs) and other potentially important noncoding RNA species. Use of high 
quality RNA inputs (RIN>8) ensured high quality libraries, which passed relatively stringent 
QC thresholds. We selected an RNA-Seq platform to enable direct comparison with other 
open access research data and to data from a future larger validation cohort. RNA-Seq is 
now becoming the platform of choice for transcriptome analysis; especially as costs of HTS 
techniques reduce over time. Our use of RNA-Seq allowed for the same technique to be 
applied across evaluation of tissue types, directly comparing samples from lesional skin, 
non-lesional skin and blood, in addition to proteomics assessment. We have evaluated a 
range of exploratory visualisations of our pilot data, which showed differing performance, 
for example a comparison of PCA and t-SNE visualisation of lesional vs. non-lesional skin 
highlighted the former method’s greater sensitivity to local effects.
The individual genes identified in differential expression analyses were not further 
evaluated, since our study is not powered for discovery and this approach has been 
comprehensively reported elsewhere (Li et al., 2014). However, at a systems level, upstream 
regulator analysis (IPA) of DEGs associated with clinical response across tissues and time 
points indicated that changes in genes controlled by the target of the drug, TNF, were the 
most predictive of response. Although this might seem intuitive, previous reports have linked 
etanercept response to interleukin (IL)-17 signalling rather than TNF early response genes 
(Zaba et al., 2009). In blood, in addition to TNF regulation, we also saw a strong interferon 
signature associated with response to etanercept, which has previously been reported in 
association with etanercept response in skin (Johnston et al., 2014) and also with TNF 
activation in inflammatory diseases (Mavragani et al., 2007, Zou et al., 2003). Comparison 
of TNF and interferon signatures across time points in association with response also shows 
an interesting pattern, with strong signals in blood at baseline, and in skin at 1 week, 
potentially indicating the genomic response to TNFi therapy (Figure 3). Concordance of 
baseline omic platforms in prediction of response demonstrated the strongest association 
between lesional skin mRNA and blood mRNA. Few response associated genes were seen in 
common across tissues and time points, notably all genes associated in more than one tissue 
were located in the major histocompatibility complex (MHC) (Supplementary Table 1). This 
correlates with previous genetic findings (Talamonti et al., 2013) supporting an immunologic 
basis to both treatment response and psoriasis pathology (Krueger, 2002).
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Whilst it is difficult to either identify or validate stable subgroups within small cohorts, we 
are confident this approach will be more informative in a larger study and preliminary 
evidence here, suggests that blood biomarkers may be an informative and less invasive 
predictor of response. We used our dataset to empirically inform a power calculation for the 
prospective study PSORT; where 80 participants are being recruited for assessment of each 
of adalimumab and ustekinumab. This demonstrates that the PSORT study is adequately 
powered to detect moderate to large treatment effects in most scenarios.
We encourage researchers to access our data in ArrayExpress (accession numbers E-
MTAB-6428, E-MTAB-6555 and E-MTAB-6556) and review our supplementary R 
Markdown documents on GitHub to learn more about our pipeline and to fully reproduce 
our results. Data sharing and open source analytics are the obvious solution to the 
reproducibility crisis that plagues clinical and omic research today, and is becoming more 
commonplace in fields which are advancing stratified medicine (Omberg et al., 2013).We 
believe that open access to data and code should be the norm in life science research, not the 
exception (Foulkes et al., 2017).
Our study went beyond analysis of a single technology appraisal of treatment prediction in 
one cohort to provide a scalable framework for predictive and inferential analysis of multi-
omic data for clinical dermatology. Despite our small sample size, we were able to detect 
consistent signals of differential expression and build machine-learning models that in 
adequately powered studies may offer complementary information to clinical factors in the 
prediction of outcome. We suggest this ability to detect signals is in part due to the use of a 
single clinician for cohort ascertainment and sample processing thereby minimising clinical 
confounders and batch issues and allowing bioinformatics expertise to synergise with 
clinical research strategy from conception through analysis. These results have implications 
for ongoing studies. Our exploration has provided the framework for the generation of a 
large-scale omics dataset from PSORT. The signals we have detected will be examined for 
validity using the same robust analytical pipeline in PSORT, which we demonstrate is 
substantially powered to detect true biomarkers of response to therapy. Likewise as omics 
techniques are applied to other dermatological diseases such as atopic eczema (Suarez-
Farinas et al., 2015) at the same time as an expansion in biologic therapies is occurring 
(Blauvelt et al., 2017), genomic approaches to personalisation and stratification of therapies 
may have broad applicability.
Materials and Methods
Prospective observational study
Ten participants commencing etanercept therapy (50mg by subcutaneous injection 
administered once weekly) were recruited (providing written, informed consent) to take part 
in a prospective clinical observational study entitled ‘Pharmacogenomic signatures of 
treatment response in psoriasis’ (UK Research Ethics Committee reference 11/NW/0500; 
protocol available in supplementary materials). Patients had a diagnosis of chronic plaque 
psoriasis of early onset (≤ 40 years) disease, were White of European ancestry (to third 
generation) and had not received prior systemic or biologic treatments in at least two weeks 
(or four × t½ of last treatment, whichever was longer). Of the 10 participants, nine were 
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naïve to biologic therapy. Patients completed detailed demographic questioning, including 
reporting information on comorbidities and concomitant medication. Disease severity and 
response to therapy were assessed using the PASI, Physician Global Assessment (PGA) and 
DLQI. Clinical samples including blood and skin biopsies were collected at baseline, one 
week (following the second injection of etanercept) and 12 weeks of treatment. Adherence 
to therapy was assessed, including witnessed/administered injections at the initial visit, self-
reporting of timings of injections between visits and monitored drug levels at the final visit. 
The same physician and research nurse conducted all research visits (ACF and JH).
Laboratory methodology
For skin and blood sampling techniques, RNA sequencing details and Somalogic proteomic 
analysis methodology, please refer to Supplementary Materials and Methods.
Genomic data analysis workflow—The RNA-Seq data is available Array Express 
(accession number). The analysis code is available in our public GitHub repository (https://
github.com/C4TB/PSORT_ETN_pilot). Executable R scripts and R Markdown documents 
are available in order to allow complete reproduction of our analysis workflow. All analyses 
were conducted in R version 3.4.0.
Upstream regulator analysis—Functional analysis of systems-level upstream regulators 
responsible for observed differential gene expression related to response was performed 
using the Upstream Regulator function in Ingenuity Pathways Analysis (IPA; Ingenuity 
Systems), using all genes with nominal response p ≤ 0.05 as input. For all gene set 
enrichment analyses, a right-tailed Fisher’s exact test was used to calculate a pathway p-
value determining the probability that each biological function assigned to that data set was 
due to chance alone. All enrichment scores were calculated in IPA using all transcripts that 
passed QC as the background data set. Upstream regulator analysis is based on prior 
knowledge of expected effects between regulators and their known target genes according to 
the IPA database. The prediction of activation state is based on the global direction of 
changes of differentially expressed genes, a z-score is calculated and determines whether 
gene expression changes for known targets of each regulator are correlated with what is 
expected from the literature for an activation of this pathway. In this exploratory analysis we 
emphasized power over type 1 error, using a nominal z score threshold of z > 2 to indicate 
activation or z < −2 to indicate inhibition. For definition of response and differential 
expression analyses, please see Supplementary Materials and Methods.
Clustering—Supervised and unsupervised clusters differ with respect to how genes were 
filtered across the two groupings. For our supervised analysis, we filtered out the bottom 
half of probes by association with biologic response, as determined by moderated t-tests. 
With unsupervised clusters, we filtered by the leading fold change between each sample pair, 
as implemented in limma (Ritchie et al., 2015). Next, we projected the data in two 
dimensions using t-SNE (Van Der Maaten et al., 2008). Finally, we clustered the samples 
using k-medoids, also known as the PAM algorithm (Kaufman and Rousseeuw, 1990). 
Ideally, optimal cluster number k would be established via a resampling procedure such as 
consensus clustering (Monti et al., 2003). However, given our limited sample size, we chose 
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to fix k = 2, separating samples into two groups that would ideally correspond to responders 
and non-responders. Cross-platform concordance was evaluated using the mutual 
information between cluster assignments, a dependency metric that ranges from 0 to 1 bit 
when k = 2.
Predictive Models—We built and evaluated a series of random forest models using 
continuous response measures to compare the predictive power associated with different 
platforms. To do so, we created a pipeline using tools from the caret package for 
classification and regression training (Kuhn and Johnson, 2013).
Continuous models, designed to predict a patient’s percent change in PASI, were tuned 
using the root mean square error (RMSE) loss function, which is standard for linear 
regressions. Response was defined by a winsorised the delta PASI distribution, as explained 
above. We selected variables using the two-loop RFE algorithm outlined in (Kuhn and 
Johnson, 2013). For each platform, we tested 20 different subsets of probes, with 
dimensionality determined by an exponential function so that relatively low-dimensional 
subsets of the feature space were explored more closely than high-dimensional subsets. 
Performance was evaluated using 10-fold cross-validation. Lower RMSE values indicate 
more predictive models.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Study Overview
Participants were assessed at baseline, week one and week 12 of therapy. Participant 
sampling comprised blood testing, urine collection, lesional and non-lesional skin biopsies 
(from photoprotected sites on the lower back/buttock, from the edge of plaques and at a 
minimum distance from previous biopsy sites). RNA-Seq was conducted on mRNA from 
blood, lesional and non-lesional skin and miRNA from blood. Proteomic assessment was 
conducted on serum.
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Figure 2. 
Differential expression of mRNA, miRNA and protein across time and across tissue. a) The 
number of biomolecules declared differentially expressed between responders and non-
responders at 10% FDR for each tissue, time point, and platform. The number of tests vary 
between platforms, mRNA (19304), miRNA (3632), protein (1129) b) Model metrics for 
random forests; we report mean (SD) predictive error and number of features retained after 
recursive feature elimination for each data platform and response type. Continuous response 
models were evaluated using root mean square error (RMSE), while categorical models were 
tuned with cross entropy loss. Asterisks denote the top performing data platform for each 
class of random forests.
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Figure 3. 
Top upstream regulators across genes differentially expressed in relation to etanercept 
differential expression (p<0.05) response in psoriasis. Top 30 upstream regulators 
demonstrated. The prediction of activation state is based on the global direction of changes 
of genes with differential expression p<0.05. The nominal limit of significance (z-score < −2 
or > 2) is indicated by the Activation z-score colour scale.
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Figure 4. 
Concordance of platforms at prediction of PASI 75. a) Heatmap depicting the concordance 
of cluster assignments across platforms as determined by supervised methods. b) Box plots 
demonstrate the distribution of cross-validated root mean square error (RMSE) over ten 
folds for a series of random forests models with recursive feature elimination trained to 
predict the change in PASI using only baseline samples. Lower RMSE values indicate more 
predictive models
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Table 1.
Summary of clinical characteristics of included participants
Variable Patients (n = 10)
Age, mean (years) 43
Sex F 2, M 8
Weight, kg (mean ± SD) 94.3 ± 17.7
BMI (mean ± SD) 30.6 ± 5.5
Age at onset of psoriasis (years) mean ± SD 17 ± 11
Baseline PASI; mean ± SD 20.3 ± 8.8
PASI at week 12; mean ± SD 6.8 ± 3.9
Baseline DLQI; mean ± SD 20.1 ± 9.3
DLQI at week 12; mean ± SD 4.5 ± 3.4
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